Apply Give

Other ways to search: Events Calendar | UTHSC | UTHSC News

Peer-Reviewed Selected Publications

2024

  1. Asemota S, Effah W, Holt J, Johnson D, Cripe L, Ponnusamy S, Thiyagarajan T, Khosroseshki Y, Hwang D, He Y, Grimes B, Fleming MD, Pritchard FE, Hendrix A, Fan M, Jain A, Choi HY, Makowski L, Hayes DN, Miller DD, Pfeffer LM, Santhanam B, and Narayanan R*. A Molecular Switch from Tumor Suppressor to Oncogene in ER+ve Breast Cancer: Role of Androgen Receptor, JAK-STAT and Lineage Plasticity. Proc. Natl. Acad. Sci. 121(40): e2406837121, 2024.

  1. Effah W, Khalil M, Hwang DJ, Miller DD, and Narayanan R. Advances in the Understanding of Androgen Receptor Structure and Function and in the Development of Next-Generation AR-Targeted Therapeutics. Steroids. 210:109486, 2024

  1. Joseph SC, Simon SE, Bohm MS, Kim M, Pye ME, Simmons BW, Graves DG, Thomas-Gooch SM, Tanveer UA, Holt JR, Ponnusamy S, Sipe LM, Hayes DN, Cook KL, Narayanan R, Pierre JF, and Makowski L. FXR Agonism with Bile Acid Mimetic Reduces Pre-Clinical Triple-Negative Breast Cancer Burden. Cancers. 16(7): 1368, 2024.

2023

  1. Asemota S, Effah W, Young KL, Holt J, Cripe L, Ponnusamy S, Thiyagarajan T, Hwang DJ, He Y, Mcnamara K, Johnson D, Wang Y, Grimes B, Khosrosereshki Y, Hollingsworth T, Fleming MD, Pritchard FE, Hendrix A, Khan F, Fan M, Makowski L, Yin Z, Sasano H, Hayes DN, Pfeffer LM, Miller DD, and Narayanan R*. Identification of a Targetable JAK-STAT Enriched Androgen Receptor (AR) and AR Splice Variant Positive Triple Negative Breast Cancer Subtype. Cell Reports. 42(12): 113461, 2023.
  2. Hwang DJ, He Y, Ponnusamy S, Thiyagarajan T, Mohler ML, Narayanan R, and Miller DD. Metabolism-Guided Selective Androgen Receptor Antagonists: Design, Synthesis, and Biological Evaluation for Activity Against Enzalutamide-Resistant Prostate Cancer. J. Med. Chem. 66(5): 3372-3392, 2023
  3. Thiyagarajan T, Ponnusamy S, Hwang DJ, He Y, Asemota S, Young KL, Johnson DL, Bocharova V, Zhou W, Jain AK, Petricoin EF, Yin Z, Pfeffer LM, Miller DD, and Narayanan R*. Inhibiting Androgen Receptor Splice Variants with Cysteine-Selective Irreversible Covalent Inhibitors to Treat Prostate Cancer. Proc. Natl. Acad. Sci., 120(1): e2211832120. 2023.

2022

  1. Li M, Li L, Asemota S, Kakhniashvilli D, Narayanan R, Wang X, and Liao F. Reciprocal interplay between OTULIN-LUBAC determines genotoxic and inflammatory NF-kB signal responses. Proc. Natl. Acad. Sci. 119(33): e2123097119, 2022.
  2. Mitachi K, Mingle D, Effah W, Sanchez-Ruiz A, Hevener KE, Narayanan R, Clemons WM Jr, Sarabia F, and Kurosu M. Concise Synthesis of Tunicamycin V and Discovery of a Cytostatic DPAGT1 Inhibitor. Angewandte Chemie. 61(31): e202203225. 2022.

 

2021

  1. He Y, Hwang DJ, Ponnusamy S, Thiyagarajan T, Mohler ML, Narayanan R, and Miller DD. Exploration and biological evaluation of basic heteromonocyclic propenamide derivatives as SARDs for the treatment of enzalutamide-resistant prostate cancer. J. Med. Chem., 64(15): 11045-11062, 2021.
  1. Pingili AK, Chaib M, Sipe LM, Miller EJ, Teng B, Sharma R, Yarbro JR, Asemota S, Al Abdallah Q, Mims TS, Marion TN, Daria D, Sekhri R, Hamilton AM, Troester MA, Jo H, Choi HY, Hayes DN, Cook KL, Narayanan R, Pierre JF, Makowski L. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. Cell Reports. 35(12): 109285, 2021.

2020

 

  1. He Y, Hwang DJ, Ponnusamy S, Thiyagarajan T, Mohler ML, Narayanan R, Miller DD. Pyrazol-q-yl-Propanamides as Selective Androgen Receptor Degraders (SARDs) and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer. J. Med. Chem. 63: 12642-12665, 2020.

 

  1. Wang W, Li M, Ponnusamy S, Chi Y, Xue J, Fahmy B, Fan M, Miranda-Carboni GA, Narayanan R, Wu J, Wu ZH. ABL-1-Dependent OTULIN Phosphorylation Promotes Genotoxic  Wnt/β-Catenin Activation to Enhance Drug-Resistance in Breast Cancers. Nat. Commun. 11(1): 3965, 2020.

2019

  1. Ponnusamy S, Asemota S, Schwartzberg LS, Guestini F, McNamara KM, Pierobon M, Font-Tello A, Qiu X, Xie Y, Rao PK, Thiyagarajan T, Grimes B, Johnson DL, Fleming MD, Pritchard FE, Berry MP, Oswaks R, Fine RE, Brown M, Sasano H, Petricoin EF, Long HW, and Narayanan R*. Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers. iScience. 23: 21:341-358, 2019.

 

  1. Ponnusamy S, He Y, Hwang DJ, Thiyagarajan T, Houtman R, Bocharova V, Sumpter BG, Fernandez E, Johnson DL, Du Z, Pfeffer LM, Getzenberg RH, McEwan IJ, Miller DD, and Narayanan R*. Orally-Bioavailable Androgen Receptor Degrader, A Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research, 25(22): 6764-6780, 2019.

 

  1. Hwang DJ, He Y, Ponnusamy S, Mohler ML, Thiyagarajan T, McEwan IJ, Narayanan R, and Miller DD. A new generation of selective androgen receptor degraders (SARDs): Our initial design, synthesis, and biological evaluation of new compounds with enzalutamide-resistant prostate cancer activity. J. Med. Chem. 62: 491-511, 2019.

2018
16. Narayanan R, Coss CC, and Dalton JT. Development of Selective Androgen Receptor Modulators
(SARMs). Mol. Cell Endocrinol. 465, 134-142, 2018.

2017

17. Narayanan R*, Ponnusamy S, Miller DD. Destroying the Androgen Receptor (AR)-Potential Strategy       to Treat Advanced Prostate Cancer. Oncoscience, 4(11-12), 175-177, 2017.

18. Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB,         Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, and  Narayanan R*. Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer. Cancer Research, 77 (22), 6282-6298, 2017.

19. Ponnusamy S, Sullivan RD, You D, Zafar N, Yang CH, Thiyagarajan T, Johnson DL, Barrett ML, Koehler NJ, Star M, Stephenson EJ, Bridges D, Cormier SA, Pfeffer LM, and Narayanan R*. Androgens Increase Lean Mass, Improve Cardiopulmonary Functions and Extend Survival in Preclinical Models of Duchenne Muscular Dystrophy. Human Molecular Genetics, 26 (13), 2526-40, 2017.

19. Ponnusamy S, Tran NQ, Thiyagarajan T, Miller DD, Bridges D, and Narayanan R*. An Estrogen Receptor β-Selective Agonist Inhibits Non-Alcoholic Steatohepatitis (NASH) in Preclinical Models by Regulating Bile Acid and Xenobiotic Receptors. Experimental Biology and Medicine. 242 (6), 606-616, 2017.

20. Ponnusamy S, Sullivan RD, Thiyagarajan T, Tillmann H, Getzenberg RG, and Narayanan R*.
Tissue Selective Androgen Receptor Modulators (SARMs) Increase Pelvic Floor Muscle Mass in
Ovariectomized Mice. J. Cellular Biochem. 118 (3), 640-646, 2017.

21. Ponnusamy S, Tran QT, Harvey I, Smallwood HS, Thiyagarajan T, Banerjee S, Dalton JT, Sullivan RD, Miller DD, Bridges D, and Narayanan R*. Estrogen Receptor-β (ER-β)- and its Selective Ligand Increases Mitochondrial Function and Promotes Energy Expenditure Resulting in Reduced Adiposity. FASEB J. 31 (1), 266-281, 2017.